KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Issued
Ratios

Regeneron Pharmaceuticals (REGN) Other Gross PP&E Adjustments (2016 - 2025)

Regeneron Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 16 years, most recently at $7.2 billion for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at $7.2 billion for Q4 2025, up 13.7% from a year ago — trailing twelve months through Dec 2025 was $7.2 billion (up 13.7% YoY), and the annual figure for FY2025 was $7.2 billion, up 13.7%.
  • Other Gross PP&E Adjustments for Q4 2025 was $7.2 billion at Regeneron Pharmaceuticals, up from $6.3 billion in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for REGN hit a ceiling of $7.2 billion in Q4 2025 and a floor of -$15.6 million in Q3 2022.
  • Median Other Gross PP&E Adjustments over the past 5 years was $5.2 billion (2022), compared with a mean of $4.7 billion.
  • Biggest five-year swings in Other Gross PP&E Adjustments: increased 13.25% in 2022 and later increased 14.71% in 2023.
  • Regeneron Pharmaceuticals' Other Gross PP&E Adjustments stood at $4.2 billion in 2021, then grew by 13.25% to $4.8 billion in 2022, then increased by 14.71% to $5.5 billion in 2023, then grew by 14.06% to $6.3 billion in 2024, then rose by 13.7% to $7.2 billion in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $7.2 billion (Q4 2025), $6.3 billion (Q4 2024), and $5.5 billion (Q4 2023) per Business Quant data.